Phase I and Pharmacokinetic Trial of the Novel Taxane BMS-184476 Administered as a 1-Hour Intravenous Infusion in Combination with Cisplatin Every 21 Days

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5221-5227

  Sun, Weijing ^a   Stevenson, James P ^a   Gallagher, Maryann L ^a   Vaughn, David ^a   Hahn, Steven M ^a   Haller, Daniel G ^a   Cohen, Marvin ^b   Kopit, Justin ^c   Gallant, Gilles ^b   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^c B M Squibb Phamaceut Res Inst ^*

Author keywords

[No Author keywords available]

Indexed keywords

BMS 184476; CISPLATIN; ETHER DERIVATIVE; GLYCOPROTEIN P; PACLITAXEL; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; MALE; MESOTHELIOMA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MYALGIA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SENSORY NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR XENOGRAFT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; SALVAGE THERAPY; TAXOIDS;

EID: 10744222643     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rowinski, E. K., and Donehower, R. C. Paclitaxel. N. Engl. J. Med., 332: 1004-1014, 1995.
2. Cortes, J. E., and Pazdur R. Docetaxel. J. Clin. Oncol., 13: 2643-2655, 1995.
3. Choy, H. Taxanes in combined-modality therapy for solid tumors. Oncology (Huntingt.), 13(Suppl. 5): 23-38, 1999.
4. Milas, L., Hunter, N. R., Mason, K. A., Milross, C. G., Saito, Y., and Peters, L. J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res., 55: 3564-3568, 1995.
5. Rose, W. C., Fairchild, C., and Lee, F. Y. F. Preclinical antitumor activity of two novel taxanes. Cancer Chemother. Pharmacol., 47: 97-105, 2001.
6. Kim, J. S., Amorino, G. P., Pyo, H., Cao, Q., and Choy, H. The novel taxane analogs BMS-184476 and BMS-188797, potentiate the effects of radiation therapy in vitro and in vivo against human lung cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 51: 525-534, 2001.
7. Hidalgo, M., Aylesworth, C., Hammond, L. A., Britten, C. D., Weiss, G., Stephenson, J., Jr., Schwartz, G., Patnaik, A., Smith, L., Molpus, K., et al. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J. Clin. Oncol., 79: 2493-2503, 2001.
8. Kim, Y. H., Shin, S. W., Kim, B. S., Kim, J. H., Kim, J. G., Mok, Y. J., Kim, C. S., Rhyu, H. S., Hyun, J. H., and Kim, J. S. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer (Phila.), 85: 295-301, 1999.
9. Maiche, A. G., Jekunen, A. P., Kaleva-Kerola, J., and Sequeiros, G. B. High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma. Cancer (Phila.), 88: 1863-1868, 2000.
10. Piver, M. S., Ghamande, S. A., Eltabbakh, G. H., and O'Neill-Coppola, C. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - a Phase II study. Gynecol. Oncol., 75: 334-337, 1999.
11. Hussain, M., Gadgeel S Kucuk, O., Du, W., Salwen, W., and Ensley, J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer (Phila.), 86: 2364-2369, 1999.
12. WHO. Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48, Geneva, Switzerland: World Health Organization, 1979.
13. Gibaldi, M., and Perrier, D. Pharmacokinetics, 2nd Edition, pp. 409-417. New York: Marcel-Dekker Inc., 1982.
14. Sessa, C., Capri, G., Llado, A., Grasselli, G., Perotti, A., Vigano, L., Locatelli, A., Peccatori, F., Renard, J., Voi, M., et al. A dose-finding/pharmacokinetic trial of the novel taxane BMS-184476 in combination with doxorubicin. Proc. Am. Soc. Clin. Oncol., 20: 107a, 2001.
15. Stevenson, J. P., Gallagher, M., Sun, W., Vaughn, D. J., Haller, D. G., Hiller, K., Tortora, A., Gupta, E., Sonnichsen, D., Skillings, J., and O'Dwyer, P. Phase I clinical and pharmacokinetic study of the taxane analog BMS-184476 administered as a 1-hour IV infusion in combination with carboplatin every 21 days. Proc. Am. Assoc. Cancer Res., 41: 608, 2000.
16. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., and Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 346: 92-98, 2002.
17. Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., and Willingham, M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA, 84: 7735-7738, 1987.
18. Henningsson, A., Karlsson, M. O., Vigano, L., Gianni, L., Verweij, J., and Sparreboom, A. Mechanism-based pharmacokinetic model for paclitaxel. J. Clin. Oncol., 19: 4065-4073, 2001.
19. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Lacatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.